Erlotinib or best supportive care for third-line treatment of advanced non-small-cell lung cancer: A real-world cost-effectiveness analysis

Erlotinib in Previously Treated Non–Small-Cell Lung Cancer

Frances A. Shepherd, José Rodrigues Pereira, Tudor–Eliade Ciuleanu et al. · New England Journal of Medicine · 2005 · 5.4K citations · Full text

Erlotinib in Lung Cancer — Molecular and Clinical Predictors of Outcome

Ming‐Sound Tsao, Akira Sakurada, Jean-Claude Cutz et al. · New England Journal of Medicine · 2005 · 1.8K citations

Symptom Improvement in Lung Cancer Patients Treated With Erlotinib: Quality of Life Analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21

Andrea Bezjak, Dongsheng Tu, Lesley Seymour et al. · Journal of Clinical Oncology · 2006 · 294 citations · Full text

Phase III Study by the Norwegian Lung Cancer Study Group: Pemetrexed Plus Carboplatin Compared With Gemcitabine Plus Carboplatin As First-Line Chemotherapy in Advanced Non–Small-Cell Lung Cancer

Bjørn Henning Grønberg, Roy M. Bremnes, Øystein Fløtten et al. · Journal of Clinical Oncology · 2009 · 289 citations · Full text

Cancer Quality, Gemcitabine Plus Carboplatin, Cancer Management +17

Randomized Phase III Trial of Gefitinib versus Docetaxel in Non–Small Cell Lung Cancer Patients Who Have Previously Received Platinum-Based Chemotherapy

Dae Ho Lee, Keunchil Park, Joo Hang Kim et al. · Clinical Cancer Research · 2010 · 176 citations · Full text